Cardiac allograft vasculopathy (CAV) accounts for major morbidity and mortality late in the heart transplant (HTx) history. The role of antibodies (Abs) directed against human leukocyte antigens (HLA) and non-HLA antigens in the pathogenesis of CAV are still under investigation.
For a long time cardiologists have not been able to explain why the problem of cardiac arrhythmia in a heart transplant recipient practically disappears. In fact, this issue has never been raised for discussion. At the same time, my new theory of arrhythmias (NTA) has been discussed at conferences and in mass media for the last 4 years.